client logo
Version: 1.0.0 | Published: 28 Aug 2026 | Updated: 15 days ago

The IMPRESS study: Improving Cyberknife Spinal Stereotactic Radiotherapy in Difficult to Treat Cases

Dataset

Documentation

Description:
For certain patients with particular tumour characteristics prone (lying on your front) spine stereotactic radiotherapy (SBRT) may be superior in radiotherapy delivery outcomes than supine (lying on your back) treatment. The study requires patients to undergo an additional "investigational" position CT scan which will be either prone or supine depending on which position has been recommended as the treatment position for spine SBRT treatment. All ten patients will have both supine and prone setup and imaging so radiotherapy plan comparison can take place. The outcome measures that are expected to improve patient treatments include better coverage of the tumour and less radiotherapy dose to normal tissues to reduce toxicity. Patients then continue on their standard planning pathway and complete spinal SBRT treatment in the position recommended by their physician and agreed at a Royal Marsden stereotactic radiotherapy multidisciplinary meeting. Patient treatment did not alter from spine SBRT in the position recommended originally by their direct care team - the ‘investigational’ position imaging was not available for the direct care team.

Coverage

Spatial:
Sutton LB, United Kingdom
Typical Age Range:
18-150
Follow Up:
6 - 12 Months
Pathway:
Patients undergoing Cyberknife treatment to spinal metastasis who consent to the study, undergo an additional CT scan acquisition at CT radiotherapy planning - regardless of which position was recommended as the treatment position for spine SBRT treatment - ie all participating patients have a prone and supine CT scan available to compare radiation therapy plans, then continue on their standard planning pathway and complete spinal SBRT treatment in the position recommended by their physician and agreed at a Royal Marsden stereotactic radiotherapy multidisciplinary meeting. Organs at risk dose, Comfort scores, CT and MRI registration on tumour target delineation and Treatment time duration are measured at time of imaging (between supine and prone positioning). PTV isodose coverage compared the both groups (radiotherapy plans delivered in prone and supine positions) through study completion (an average of 1 year). Only 6 of the planned 10 participants were recruited

Provenance

Origin

Purposes:
Study
Sources:
Other
Collection Situations:
Cohort, study, trial

Temporal

Accrual Periodicity:
Static
Start Date:
29 July 2020
End Date:
01 May 2025
Time Lag:
Not applicable

Accessibility

Access

Access Rights:
in progress
Access Service:
Although not required, there is an option to use The Royal Marsden’s Trusted Research Environment and informatics platform: BRIDgE (Biomedical Research Informatics Digital Environment). BRIDgE is managed by The Royal Marsden’s Information Team with support by the NIHR Biomedical Research Centre at The Royal Marsden and ICR. The aim of the platform is to transform clinical practice and improve outcomes for patients by enabling researchers to access real-world cancer data within secure, collaborative, cloud-based workspaces. Learn more by visiting the BRIDgE site within the NIHR BRC area of The Royal Marsden and ICR website: https://www.cancerbrc.org/BRIDgE
Access Request Cost:
Depends on type of access. Costing available on application.
Delivery Lead Time:
Variable
Jurisdictions:
UK
Data Controller:
Royal Marsden NHS Foundation Trust
Data Processor:
Royal Marsden NHS Foundation Trust

Usage

Data Use Limitations:
Research-specific restrictions
Data Use Requirements:
  • Ethics approval required
  • Institution-specific restrictions
  • Not for profit use
  • User-specific restriction
Resource Creators:
The Royal Marsden NHS Foundation Trust; The Royal Marsden Cancer Charity; NIHR Biomedical Research Centre at The Royal Marsden and the ICR

Format and Standards

Vocabulary Encoding Schemes:
LOCAL
Conforms To:
LOCAL
Languages:
en

Observations

Statistical Population
Population Description
Population Size
Measured Property
Observation Date
Persons
Patients recruited from single site over several years. Observation date given is last recruitment date.
6
07 January 2025